Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAR2A | P13861 | 9/20 | 0.94 |
| ▸ | PRKAR2B | P31323 | 7/20 | 0.94 |
| ▸ | EIF4E | P06730 | 1/20 | 0.59 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.56 |
| ▸ | MDM4 | O15151 | 5/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17568826 | 0.71 | MDM2 (0.58) | PRKAR2APRKAR2BEIF4EEIF4EBP1MDM2 | |
| SCHEMBL18053128 | 0.71 | MDM2 (0.58) | PRKAR2APRKAR2BEIF4EEIF4EBP1MDM2 | |
| Sulanemadlin SCHEMBL29372019 | 0.70 | MDM2 (1.00) | MDM2MDM4PCSK9 | |
| SCHEMBL22086611 | 0.67 | TFPI (0.58) | — | |
| SCHEMBL24473539 | 0.67 | NTSR2 (0.61) | PRKAR2APRKAR2BEIF4EEIF4EBP1ESR1 | |
| SCHEMBL18053760 | 0.67 | MDM2 (0.53) | PRKAR2APRKAR2BEIF4EEIF4EBP1MDM2 | |
| SCHEMBL24473602 | 0.67 | NTSR2 (0.71) | PRKAR2APRKAR2BEIF4EEIF4EBP1 | |
| SCHEMBL24473663 | 0.66 | NTSR2 (0.61) | PRKAR2APRKAR2BEIF4EEIF4EBP1 | |
| SCHEMBL24473339 | 0.66 | NTSR2 (0.73) | PRKAR2APRKAR2BEIF4EEIF4EBP1 | |
| SCHEMBL24473505 | 0.66 | NTSR2 (0.73) | PRKAR2APRKAR2BEIF4EEIF4EBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230220019-A1 | CHEMICALLY-STABILIZED ALLOSTERIC MODULATORS OF LEUCINERICH REPEAT KINASE 2 (LRRK2) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-114449621-B | Method, device and storage medium for saving electric quantity consumption of multilink terminal | 极米科技股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4110357-A1 | CHEMICALLY-STABILIZED ALLOSTERIC MODULATORS OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) | University of Georgia Research Foundation, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-114449621-A | Method, device and storage medium for saving electric quantity consumption of multilink terminal | 成都极米科技股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022088767-A1 | METHOD AND APPARATUS FOR REDUCING ELECTRICITY CONSUMPTION OF MULTI-LINK TERMINAL, AND STORAGE MEDIUM | 成都极米科技股份有限公司 | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220019-A1 | CHEMICALLY-STABILIZED ALLOSTERIC MODULATORS OF LEUCINERICH REPEAT KINASE 2 (LRRK2) | LRRK2, TLK2, LMTK2 | PRKAR2A 74/4885PRKAR2B 101/4885EIF4E 452/4885 |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | PRKAR2A 227/4885PRKAR2B 192/4885EIF4E 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.